Development of a Recombinant Xenogeneic Tumor Necrosis Factor Alpha Protein Vaccine To Protect Mice from Experimental Colitis

Previous studies have highlighted the efficacy of tumor necrosis factor alpha (TNF-α) inhibitors, including monoclonal antibodies and soluble receptors, in the treatment and management of intestinal bowel disease (IBD). However, because of the immunogenicity of xenogeneic TNF-α inhibitors, antidrug...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Vaccine Immunol
Prif Awduron: Wan, Yang, Li, Meng, Zhang, Hailong, Zheng, Xiuran, Yu, Chaoheng, He, Gu, Luo, Yan, Yang, Li, Wei, Yuquan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2015
Pynciau:
Vaccines
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658592/
https://ncbi.nlm.nih.gov/pubmed/26466602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00331-15
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg